Roivant Sciences SEC Filings

Roivant Sciences (ROIV) disclosure shows a group of Viking Global entities and three executive committee members collectively beneficially own 34,237,779 Common Shares, representing 5.02% of the 682,229,832 shares outstanding reported by the issuer.

The filing (Schedule 13G, Amendment No. 5) lists each reporting person and the number of shares for which they have shared voting and dispositive power (VGI: 34,237,779; VGP: 18,346,865; VGEM: 17,979,927; VLFM: 6,384,710; VGOP: 9,506,204; VGEII: 366,938). The reporting persons state the securities were not acquired to change or influence control of the issuer.

QVT Financial LP reported beneficial ownership of 29,381,635 common shares of Roivant Sciences Ltd., representing 4.30% of the outstanding class. The filing is a Schedule 13G (Amendment No. 5) covering common shares (CUSIP G76279101) with the relevant event date noted as 06/30/2025. QVT reports sole voting and dispositive power over all shares disclosed. The statement is a passive ownership disclosure rather than an active solicitation filing and indicates transparency about a sub-5% stake rather than a controlling position.

Roivant Sciences Ltd. reported a quarterly net loss attributable to Roivant of $223.4 million for the three months ended June 30, 2025, compared with net income of $95.3 million in the prior-year period, driven by higher operating expenses and the absence of a prior-period sale gain.

The company held $1.24 billion in cash and cash equivalents and $3.26 billion in marketable securities at quarter-end, totaling approximately $4.50 billion in liquid assets. Total assets were $5.03 billion and total shareholders' equity was $4.82 billion. Revenue for the quarter was $2.17 million, down from $7.99 million, while research and development expense rose to $152.9 million and general and administrative expense increased to $134.0 million. Net cash used in operating activities was $204.4 million and the company completed a $1.5 billion share repurchase program, spending $208.3 million in the quarter, and authorized a new $500 million repurchase facility.

Roivant Sciences Ltd. filed a Current Report on Form 8-K stating that on August 11, 2025 the company issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The press release is attached to the report as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104.

The filing clarifies that the information in the Item 2.02 section and the attached exhibit is not deemed "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings except by express reference. The report is signed by Keyur Parekh as Authorized Signatory on August 11, 2025, and identifies the company’s Nasdaq trading symbol as ROIV.

Roivant Sciences (ROIV) Form 4, filed 1 Aug 2025, discloses a large equity grant to President & Vant Chair Frank Torti. On 30 Jul 2025 he received (i) 1,836,547 time-based RSUs that vest 20 % after one year and quarterly thereafter, and (ii) 11,900,000 performance-based PSUs split into six price-hurdle tranches ($15–$30). Each tranche vests only after both a share-price test (30-day VWAP before 26 Jul 2029) and one additional year of service, followed by a two-year holding lock-up. The award was granted at $0 cost; no open-market buying occurred.

Post-grant, Torti’s beneficial ownership rises to 13,736,547 common shares, all held directly. While the structure tightly links vesting to long-term price performance, full issuance would add material dilution if all hurdles are met.

Roivant Sciences Ltd. (ROIV) – Form 4 filing: President & Immunovant CEO Eric Venker reported an equity award on 30 Jul 2025. The grant comprises 198,413 restricted stock units (RSUs) for common shares at a cost basis of $0. Vesting begins 20 May 2025, with 25 % vesting on the first anniversary and the balance in 12 equal quarterly tranches, contingent upon continued service.

Post-grant, Venker’s direct beneficial ownership rises to 1,660,636 common shares. The filing contains no open-market purchases or sales; therefore, it signals executive retention rather than a valuation view. The transaction represents routine equity compensation and has minimal immediate dilution or cash-flow impact for shareholders.

Roivant Sciences (ROIV) – Form 4 filing (30 Jul 2025)

CFO Richard Pulik reported an automatic disposition of 1,919 common shares on 28 Jul 2025 at an implied price of $11.35. The transaction is coded “F”, indicating the issuer withheld shares to cover taxes due upon the vesting of previously granted restricted stock units (RSUs); no open-market sale occurred. After the net-settlement, Pulik retains 397,553 shares, so the shares surrendered equal roughly 0.5 % of his post-transaction holdings. Because the activity is tax-related and immaterial to overall ownership, it is typically viewed as routine rather than a directional signal on the company’s prospects.